Quinoline Derivative and S1P Modulator Combination for Inflammatory Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases, such as inflammatory bowel disease, often come with side effects like bradyarrhythmia, atrioventricular blocks, lymphopenia, and increased infection risk, and there is a need for alternative therapies that are more effective and have fewer side effects.
Innovation Solution
A combination therapy involving 8-Chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine or its prodrug/metabolite with a S1P receptor modulator, which can reduce the dose of the S1P receptor modulator required, thereby minimizing its side effects while maintaining or enhancing its efficacy in treating inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a S1P receptor modulator is used to treat inflammatory diseases, then the anti-inflammatory efficacy is improved, but the side effects (bradyarrhythmia, AV blocks, lymphopenia, infection risk) increase
Solution Approach 1:
The patent introduces an intermediary substance (the quinoline derivative compound) that mediates between the S1P receptor modulator and the inflammatory disease. This compound works through a different mechanism (PDE4 inhibition) to achieve anti-inflammatory effects, allowing the S1P modulator to be used at lower doses while maintaining efficacy, thereby reducing side effects like bradyarrhythmia, AV blocks, and lymphopenia
Solution Approach 2:
The patent changes the dosage parameter of the S1P receptor modulator by introducing combination therapy. By using a lower dose of the S1P modulator in combination with the quinoline derivative, the therapeutic effect is maintained while the harmful side effects are reduced. This parameter change (dose reduction) directly addresses the contradiction between efficacy and side effects
2Object-affected harmful factors
If the dose of S1P receptor modulator is reduced to minimize side effects, then the side effects decrease, but the anti-inflammatory efficacy may be compromised
Solution Approach 1:
The patent merges two different therapeutic agents with different mechanisms of action: the S1P receptor modulator and the quinoline derivative compound (PDE4 inhibitor). By combining these two agents, the total anti-inflammatory efficacy is maintained or enhanced while allowing each component to be used at lower doses, thus minimizing side effects without compromising therapeutic benefit
Solution Approach 2:
The patent creates a composite therapeutic regimen combining two distinct pharmacological agents. The quinoline derivative compound (Formula I) with its specific molecular structure acts as one component, while the S1P receptor modulator acts as another, forming a composite treatment approach that leverages synergistic or additive effects to maintain efficacy at reduced doses
Data Source
AI summary
A pharmaceutical combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, prodrug thereof or a metabolite thereof with a SIP receptor modulator or a pharmaceutically acceptable salt thereof. The compound of formula (I) has the following formula: